Sorgun Mine Hayriye, Kuzu Muge, Ozer Inci Sule, Yilmaz Volkan, Ulukan Cagrı, Cotur Levent Hafize, Tezcan Sabiha, Rzayev Sefer, Rawandi Anwar, Bakırarar Batuhan, Isikay Canan Togay
Ankara University School of Medicine, İbni Sina Hospital, Department of Neurology, Samanpazarı, Ankara Turkey. Email:
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):649-653. doi: 10.22034/APJCP.2018.19.3.649.
Introduction: Cerebrovascular disease is the second most common complication in individuals with tumours. The aim of this study was to investigate risk factors, biomarkers, etiology and prognosis of ischemic stroke in cancer patients (ISCPs). Methods: The medical records of 619 consecutive patients who were admitted with acute ischemic stroke from January 2012 to November 2014 were retrospectively evaluated. The patients were divided into two groups (group 1, patients with an active cancer prior to the onset of ischemic stroke; group 2, patients without an active cancer history). The demographic data, risk factors, NIHSS scores, thrombocyte count, D-dimer, fibrinogen and C reactive protein (CRP) level at admission, modified Rankin Scale (mRS) scores in the follow-up period and location of lesions on DWI were recorded. The Mann-Whitney U test, chi-squared test and logistic regression was used for analyzing data, p<0.05 being considered statistically significant. Results: A total of 46 (7.4%) ISCPs were included. Hyperlipidemia was significantly lower in the ISCP group (p=0.001). Elevated thrombocyte counts, D-dimer, fibrinogen and CRP levels at admission, acute multiple ischemic lesions, other causes, mortality in hospital and worse outcome were significantly related to ISCP (p<0.05). On logistic regression analysis, follow up mRS>3, acute multiple ischemic lesions located in more than one vascular territory (AMIMCT) and other causes were significantly associated with ISCP (p<0.001). Conclusion: In our study, other causes, AMIMCT and mRS>3 were more common in the ISCP group. We consider that CCS could be more suitable for detecting other causes than TOAST. Biomarkers could be important in the ISCP group.
脑血管疾病是肿瘤患者中第二常见的并发症。本研究旨在调查癌症患者缺血性卒中(ISCPs)的危险因素、生物标志物、病因及预后。方法:回顾性评估2012年1月至2014年11月连续收治的619例急性缺血性卒中患者的病历。将患者分为两组(第1组,缺血性卒中发病前患有活动性癌症的患者;第2组,无活动性癌症病史的患者)。记录人口统计学数据、危险因素、美国国立卫生研究院卒中量表(NIHSS)评分、血小板计数、D - 二聚体、纤维蛋白原和入院时C反应蛋白(CRP)水平、随访期改良Rankin量表(mRS)评分以及弥散加权成像(DWI)上的病变位置。采用Mann - Whitney U检验、卡方检验和逻辑回归分析数据,p<0.05被认为具有统计学意义。结果:共纳入46例(7.4%)ISCPs患者。ISCP组高脂血症显著低于对照组(p = 0.001)。入院时血小板计数升高、D - 二聚体、纤维蛋白原和CRP水平升高、急性多发缺血性病变、其他病因、住院死亡率及较差预后与ISCP显著相关(p<0.05)。逻辑回归分析显示,随访mRS>3、位于多个血管区域的急性多发缺血性病变(AMIMCT)和其他病因与ISCP显著相关(p<0.001)。结论:在我们的研究中,其他病因、AMIMCT和mRS>3在ISCP组中更为常见。我们认为,与急性卒中治疗Org 10172试验(TOAST)相比,脑血管病临床分类(CCS)可能更适合检测其他病因。生物标志物在ISCP组中可能很重要。